Crohn's Disease Epidemiology Forecast

Key Highlights

• Crohn’s disease and ulcerative colitis are Iifelong gastrointestinal disorders, also known as Inflammatory Bowel Diseases (IBD), that commonly present themselves in children, adolescents, and adults. 
• Crohn’s disease, a progressive form of IBD, causes chronic inflammation, leading to strictures, fistulas, and ulcers across the gastrointestinal tract, primarily affecting the terminal ileum and colon.
• In the 7MM, a total of 141,300 cases were pediatric, and 1,972,200 were adult cases. The adult cases account for around 93% of the total, while pediatric cases represent around 7% of the total burden of Crohn’s disease in 2024.
• The prevalence in Spain is slightly lower than in neighboring countries like France and the United Kingdom, but it surpasses the rates seen in countries such as Italy and Portugal.
• Among the EU4 and the UK, Germany had the highest number of Crohn’s disease cases, while Spain had the lowest number of cases.
• In 2024, the total number of prevalent cases of Crohn’s disease in the US was approximately 1.5 million, whereas Japan reported the lowest prevalence, with around 74,000 cases.

DelveInsight’s ‘Crohn’s Disease – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of Crohn’s disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Crohn’s Disease Understanding

Crohn’s Disease Overview

Crohn’s disease is a chronic inflammatory condition of the Gastrointestinal (GI) tract, classified as a type of IBD. It can affect any part of the digestive system, from the mouth to the anus, but most commonly affects the small intestine and colon. The exact cause remains unknown, though it is believed to result from a combination of genetic, environmental, and immune system factors.

Symptoms vary in severity and may include abdominal pain, diarrhea, weight loss, fatigue, and malnutrition. While there is no cure, treatment focuses on reducing inflammation, managing symptoms, and preventing complications through medications, biologics, lifestyle changes, and, in some cases, surgery. With ongoing research and advancements in targeted therapies, new treatment options continue to emerge, offering hope for improved disease management and quality of life for patients with Crohn’s disease.

Crohn’s Disease Diagnosis

Diagnosing Crohn’s disease can be challenging, as its symptoms overlap with other gastrointestinal conditions, such as ulcerative colitis and Irritable bowel Syndrome (IBS). A comprehensive approach is used, combining clinical evaluation, laboratory tests, imaging studies, and endoscopic procedures. Blood tests help detect markers of inflammation, anemia, or nutritional deficiencies, while stool tests rule out infections. Imaging techniques like CT scans, MRI, and intestinal ultrasound provide detailed views of the digestive tract to identify inflammation, strictures, or fistulas. Endoscopic procedures, including colonoscopy and upper endoscopy, allow direct visualization of the intestines and tissue biopsy for confirmation. Since no single test can definitively diagnose Crohn’s disease, physicians rely on a combination of findings to ensure accurate detection and appropriate treatment planning.

Further details related to country-based variations are provided in the reported.

Crohn’s Disease Epidemiology

The Crohn’s disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Crohn’s disease, age-specific diagnosed prevalent cases of Crohn’s disease, severity-specific diagnosed prevalent cases of Crohn’s disease, and treated cases of Crohn’s disease, in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2021 to 2034. 

• The United States contributed to the largest diagnosed prevalent population of Crohn’s disease, acquiring ~54% of the 7MM in 2024. Whereas EU4 and the UK, and Japan accounted for around 42% and 4% of the total population share, respectively, in 2024.
• Among the EU4 countries, Germany accounted for the largest number of diagnosed prevalent Crohn’s disease (299,000 cases) cases, followed by the UK (234,000 cases), whereas Spain accounted for the lowest number of cases (93,000 Cases) in 2024.
• In 2024, it was estimated that there were around 461,000 diagnosed prevalent cases of mild severity and 755,000 cases of moderate-to-severe severity in the US.
• According to DelveInsight estimates, in 2024, among the age-specific diagnosed prevalent cases of Crohn’s disease in the US, the highest number of cases was in the 18–44 years age group (~657,000), followed by 45–64 years (~298,000), 65–84 years (~104,000), 0–17 years (~81,000), and those aged 85 and above (~11,000).

Explore the evolving Crohn's Disease Market trends, key players, and future outlook.

Crohn’s Disease Report Insights

• Patient population
• Country-wise epidemiology distribution

Crohn’s Disease Report Key Strengths

• Ten years forecast
• 7MM coverage 
• Crohn’s disease epidemiology segmentation

Crohn’s Disease Report Assessment

• Unmet needs
• Current diagnostic practices